FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

2018169 citationsJournal Articlegreen Open Access

Authors

Good health and well-being

Published in: Journal of Thoracic Oncology

Volume 13, Issue 11, pp. 1733-1742

Field-Weighted Citation Impact: 7.36